[6] Another preclinical study [7] noted similar [18F]FLT responses in the presence of palbociclib in a triple negative breast cancer model with protein pRB and E2F levels significantly downregulated but not in a triple negative breast cancer model without this down regulation. The gene discussed is RB1; the disease is triple-negative breast carcinoma.